Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells

AIDS Research and Human Retroviruses

Volumn 32, Issue 2, 2016, Pages 120-124

  Iordanskiy, Sergey ^a   Kashanchi, Fatah ^a  

^a GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA;

ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CELL KILLING; CELLULAR STRESS RESPONSE; CELLULAR STRESS SIGNAL; DISEASE ERADICATION; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; S PHASE CELL CYCLE CHECKPOINT; VIRION; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; CD4+ T LYMPHOCYTE; DNA REPAIR; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; RADIATION RESPONSE; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; DNA DAMAGE; DNA REPAIR; HIV INFECTIONS; HIV-1; HUMANS; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84958981912     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2016.0006     Document Type: Article

References (62)

1. Ho YC, Shan L, Hosmane NN, et al.: Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013;155:540-551.
2. Xing S, Bullen CK, Shroff NS, et al.: Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 2011;85:6060-6064.
3. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM: Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009;25:207-212.
4. Archin NM, Liberty AL, Kashuba AD, et al.: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482-485.
5. Laird GM, Bullen CK, Rosenbloom DI, et al.: Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 2015;125:1901-1912.
6. Blazkova J, Chun TW, Belay BW, et al.: Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 2012; 206:765-769.
7. Ke R, Lewin SR, Elliott JH, Perelson AS: Modeling the effects of vorinostat in vivo reveals both transient and delayed HIV transcriptional activation and minimal killing of latently infected cells. PLoS Pathog 2015;11: e1005237.
8. Curtin NJ: DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012;12:801-817.
9. Hartlerode AJ, Scully R: Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J 2009; 423:157-168.
10. Aggarwal BB: Nuclear factor-kappaB: The enemy within. Cancer Cell 2004;6:203-208.
11. Iwahori S, Yasui Y, Kudoh A, et al.: Identification of phosphorylation sites on transcription factor Sp1 in response to DNA damage and its accumulation at damaged sites. Cell Signal 2008;20:1795-1803.
12. Lebel EA, Boukamp P, Tafrov ST: Irradiation with heavyion particles changes the cellular distribution of human histone acetyltransferase HAT1. Mol Cell Biochem 2010; 339:271-284.
13. Agbottah E, Deng L, Dannenberg LO, Pumfery A, Kashanchi F: Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology 2006;3:48.
14. OgiwaraH,UiA,OtsukaA, et al.:Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors. Oncogene 2011;30:2135-2146.
15. Valerie K, Delers A, Bruck C, et al.: Activation of human immunodeficiency virus type 1 by DNA damage in human cells. Nature 1988;333:78-81.
16. Faure E, Cavard C, Zider A, Guillet JP, Resbeut M, Champion S: X irradiation-induced transcription from the HIV type 1 long terminal repeat. AIDS Res Hum Retroviruses 1995;11:41-43.
17. Smith RA, Ingels J, Lochemes JJ, Dutkowsky JP, Pifer LL: Gamma irradiation of HIV-1. J Orthop Res 2001;19:815-819.
18. Sadaie MR, Tschachler E, Valerie K, et al.: Activation of tat-defective human immunodeficiency virus by ultraviolet light. New Biol 1990;2:479-486.
19. Ogawa Y, Kobayashi T, Nishioka A, et al.: Radiationinduced oxidative DNA damage, 8-oxoguanine, in human peripheral T cells. Int J Mol Med 2003;11:27-32.
20. Clark E, Santiago F, Deng L, et al.: Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1. J Virol 2000;74:5040-5052.
21. Shahbazi J, Lock R, Liu T: Tumor protein 53-induced nuclear protein 1 enhances p53 function and represses tumorigenesis. Front Genet 2013;4:80.
22. Haas RL: Low dose radiotherapy in indolent lymphomas, enough is enough. Hematol Oncol 2009;27:71-81.
23. Yamaguchi T, Matsuda K, Sagiya Y, et al.: p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 2001;61:8256-8262.
24. Oda K, Arakawa H, Tanaka T, et al.: p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-862.
25. Sankatsing SU, Hillebregt MM, Gras L, et al.: Prolonged decrease of CD4+ T lymphocytes in HIV-1-infected patients after radiotherapy for a solid tumor. J Acquir Immune Defic Syndr 2013;62:546-549.
26. Ulrike K, Markus H, Thomas H, et al.: NNRTI-based antiretroviral therapy may increase risk of radiation induced side effects in HIV-1-infected patients. Radiother Oncol 2015;116:323-330.
27. Faure E: X-rays-induced secretion of cellular factor(s) that enhance(s) HIV-1 promoter transcription in various nonirradiated transfected cell lines. Cell Mol Biol (Noisy-legrand) 1998;44:1275-1292.
28. Iordanskiy S, Van Duyne R, Sampey GC, et al.: Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells. Virology 2015;485:1-15.
29. Siraprapasiri P, Tharavichitkul E, Suntornpong N, et al.: Effect of radiation therapy to immunological and virological status in HIV/AIDS-cancer patients, preliminary report. J Med Assoc Thai 2011;94 Suppl 2:S88-S93.
30. Hanauske-Abel HM, Saxena D, Palumbo PE, et al.: Druginduced reactivation of apoptosis abrogates HIV-1 infection. PLoS One 2013;8:e74414.
31. Schmidtke JR, Dixon FJ: The functional capacity of xirradiated macrophages. J Immunol 1972;108:1624-1630.
32. Dhariwala FA, Narang H, Krishna M. Differential response of three cell types to dual stress of nitric oxide and radiation. Cell Biol Toxicol 2012;28:161-173.
33. Khan SZ, Hand N, Zeichner SL. Apoptosis-induced activation of HIV-1 in latently infected cell lines. Retrovirology 2015;12:42.
34. Allers K, Hutter G, Hofmann J, et al.: Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011;117:2791-2799.
35. Henrich TJ, Hu Z, Li JZ, et al.: Long-term reduction in peripheral blood HIV type 1 reservoirs following reducedintensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013;207:1694-1702.
36. Yukl SA, Boritz E, Busch M, et al.: Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog 2013;9:e1003347.
37. Dadachova E, Patel MC, Toussi S, et al.: Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med 2006;3:e427.
38. Dadachova E, Kitchen SG, Bristol G, et al.: Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PLoS One 2012;7:e31866.
39. Li CJ, Wang C, Friedman DJ, Pardee AB: Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1995;92:5461-5464.
40. Gabizon R, Mor M, Rosenberg MM, et al.: Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat. Biopolymers 2008;90:105-116.
41. Van Duyne R, Easley R, Wu W, et al.: Lysine methylation of HIV-1 Tat regulates transcriptional activity of the viral LTR. Retrovirology 2008;5:40.
42. Sivakumaran H, van der Horst A, Fulcher AJ, et al.: Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat. J Virol 2009;83:11694-11703.
43. Sakane N, Kwon HS, Pagans S, et al.: Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog 2011;7:e1002184.
44. Sampey GC, Saifuddin M, Schwab A, et al.: Exosomes from HIV-1 infected cells stimulate production of pro-inflammatory cytokines through TAR RNA. J Biol Chem 2016;291:1251-1266.
45. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V: Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 2003;278:25879-25886.
46. Zimmerman ES, Sherman MP, Blackett JL, et al.: Human immunodeficiency virus type 1Vpr induces DNA replication stress in vitro and in vivo. J Virol 2006;80:10407-10418.
47. Vassena L, Giuliani E, Matusali G, Cohen EA, Doria M. The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the ATR-mediated DNA damage response pathway. J Gen Virol 2013;94:2664-2669.
48. Klase Z, Winograd R, Davis J, et al.: HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology 2009;6:18.
49. Longo F, Marchetti MA, Castagnoli L, Battaglia PA, Gigliani F: A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV Tat proteins. Biochem Biophys Res Commun 1995;206:326-334.
50. Zhou BY, He JJ: Proliferation inhibition of astrocytes, neurons, and non-glial cells by intracellularly expressed human immunodeficiency virus type 1 (HIV-1) Tat protein. Neurosci Lett 2004;359:155-158.
51. Chen BP, Chan DW, Kobayashi J, et al.: Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J Biol Chem 2005;280:14709-14715.
52. Nagasawa M, Watanabe F, Suwa A, Yamamoto K, Tsukada K, Teraoka H: Nuclear translocation of the catalytic component of DNA-dependent protein kinase upon growth stimulation in normal human T lymphocytes. Cell Struct Funct 1997;22:585-594.
53. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
54. Shao L, Goronzy JJ, Weyand CM: DNA-dependent protein kinase catalytic subunit mediates T-cell loss in rheumatoid arthritis. EMBO Mol Med 2010;2:415-427.
55. Hill R, Lee PW: The DNA-dependent protein kinase (DNAPK): More than just a case of making ends meet? Cell Cycle 2010;9:3460-3469.
56. Callen E, Jankovic M, Wong N, et al.: Essential role for DNA-PKcs in DNA double-strand break repair and apoptosis in ATM-deficient lymphocytes. Mol Cell 2009;34:285-297.
57. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ: HIV-1 causes CD4 cell death through DNAdependent protein kinase during viral integration. Nature 2013;498:376-379.
58. Durkin SS, Guo X, Fryrear KA, et al.: HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase. J Biol Chem 2008;283:36311-36320.
59. Chandhasin C, Ducu RI, Berkovich E, Kastan MB, Marriott SJ: Human T-cell leukemia virus type 1 tax attenuates the ATM-mediated cellular DNA damage response. J Virol 2008;82:6952-6961.
60. Marriott SJ, Semmes OJ: Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005;24:5986-5995.
61. Park HU, Jeong JH, Chung JH, Brady JN: Human T-cell leukemia virus type 1 Tax interacts with Chk1 and attenuates DNA-damage induced G2 arrest mediated by Chk1. Oncogene 2004;23:4966-4974.
62. Majone F, Jeang KT: Unstabilized DNA breaks in HTLV-1 Tax expressing cells correlate with functional targeting of Ku80, not PKcs, XRCC4, or H2AX. Cell Biosci 2012;2:15.